27 de febrero de 2017 / 11:32 / en 6 meses

BRIEF-Biocryst Pharmaceuticals reports positive interim results from APEX-1 trial

Feb 27 (Reuters) - Biocryst Pharmaceuticals Inc

* Biocryst reports positive interim results from its Apex-1 trial

* Biocryst Pharmaceuticals Inc - oral BCX7353 350 mg once-daily for 28 days was generally safe and well tolerated in subjects with HAE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below